Savara (SVRA) Expected to Announce Earnings on Tuesday

Savara (NASDAQ:SVRA) is expected to issue its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect Savara to post earnings of ($0.12) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 13, 2026 at 7:00 AM ET.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Friday, March 13th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). On average, analysts expect Savara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Savara Price Performance

Shares of NASDAQ:SVRA opened at $5.14 on Monday. The stock has a fifty day simple moving average of $5.53 and a two-hundred day simple moving average of $5.08. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -9.70 and a beta of 0.31. Savara has a 12-month low of $1.89 and a 12-month high of $7.01. The company has a current ratio of 11.85, a quick ratio of 11.85 and a debt-to-equity ratio of 0.15.

Hedge Funds Weigh In On Savara

Hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its stake in Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after acquiring an additional 9,463 shares during the period. Xponance LLC bought a new stake in shares of Savara in the fourth quarter worth approximately $66,000. CIBC Bancorp USA Inc. bought a new stake in shares of Savara in the third quarter worth approximately $44,000. Prudential Financial Inc. purchased a new position in shares of Savara during the second quarter valued at approximately $30,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after purchasing an additional 4,626 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on SVRA shares. Guggenheim restated a “buy” rating on shares of Savara in a report on Tuesday, December 23rd. William Blair set a $10.00 price target on shares of Savara in a research note on Monday, March 16th. HC Wainwright reissued a “buy” rating on shares of Savara in a research report on Monday, March 16th. Wall Street Zen lowered shares of Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Finally, Oppenheimer set a $10.00 target price on shares of Savara in a report on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $9.00.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.